CN115350198B - Application of epilithocholic acid - Google Patents
Application of epilithocholic acid Download PDFInfo
- Publication number
- CN115350198B CN115350198B CN202210961982.5A CN202210961982A CN115350198B CN 115350198 B CN115350198 B CN 115350198B CN 202210961982 A CN202210961982 A CN 202210961982A CN 115350198 B CN115350198 B CN 115350198B
- Authority
- CN
- China
- Prior art keywords
- acid
- epilithocholic
- streptococcus mitis
- application
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- SMEROWZSTRWXGI-WFVDQZAMSA-N isolithocholic acid Chemical compound C([C@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-WFVDQZAMSA-N 0.000 title claims abstract description 14
- 241001134658 Streptococcus mitis Species 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000003115 biocidal effect Effects 0.000 abstract 1
- -1 epilithocholic acid Chemical class 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 11
- 239000000725 suspension Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 229960005091 chloramphenicol Drugs 0.000 description 7
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 238000011481 absorbance measurement Methods 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- LITBAYYWXZOHAW-XDZRHBBOSA-N (2s,5r,6r)-6-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]hept Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 LITBAYYWXZOHAW-XDZRHBBOSA-N 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010042276 Subacute endocarditis Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940038195 amoxicillin / clavulanate Drugs 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 238000005142 microbroth dilution method Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 229940104641 piperacillin / tazobactam Drugs 0.000 description 1
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 208000001050 sialadenitis Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- AVWRKZWQTYIKIY-UHFFFAOYSA-N urea-1-carboxylic acid Chemical compound NC(=O)NC(O)=O AVWRKZWQTYIKIY-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses an application of a known compound, namely, epilithocholic acid, in preparing medicines for resisting streptococcus mitis ATCC 49456. The experiment of the invention shows that the epilithocholic acid has good activity of inhibiting streptococcus mitis, and is a potential drug capable of replacing the existing antibiotic to inhibit streptococcus mitis.
Description
Technical Field
The present invention relates to the use of an epilithocholic acid (Epialolishocholic acid), a known compound.
Background
Bile acid is an active ingredient in bile, and is one of important ingredients involved in the digestive function of bile. The content change has important reference value in liver disease diagnosis, and the published literature discloses that bile acid has the effect of inhibiting tumors. In addition, chinese patent application 202111019726.6 discloses that cholelithiaacid has antibacterial activity against staphylococcus aureus MRSA and MSSA, escherichia coli esbls+, escherichia coli Esbls-, and pseudomonas aeruginosa. The epilithocholic acid is one of the most important secondary bile acids in intestinal tracts, and the molecular formula is as follows: c (C) 24 H 40 O 3 The structural formula is shown as follows:
disclosure of Invention
The invention discloses application of table allophanate.
The application of the epilithocholic acid in preparing the medicine for resisting streptococcus mitis is provided.
The streptococcus mitis belongs to alpha-hemolytic streptococcus (also called alpha-hemolytic streptococcus), is one of normal flora of parts of the oral cavity, the digestive tract, the genital tract and the like of a human body, is a conditional pathogenic bacterium, can cause toxic shock syndrome, subacute endocarditis, prostatitis and the like, and can also cause pneumonia, pericarditis, peritonitis, salivary gland inflammation, orofacial infection, odontogenic infection, otitis media, sinusitis and the like. It has been reported that this pathogen was isolated in the body of the affected pigs and resulted in severe morbidity and mortality in piglets, suggesting that streptococcus mitis is also pathogenic to pigs. Among the common antibiotics for pediatrics, the streptococcus mitis has different degrees of drug resistance to aztreonam, ceftriaxone, piperacillin/tazobactam and amoxicillin/clavulanate potassium, and the drug resistance rate reaches 42.3% -48.1%. These antibiotics are still currently the usual drugs for pediatric pneumonia. Bacterial resistance is a global problem, but the development of corresponding antibiotics is slow and the form is very severe, so a new antibacterial drug or antibacterial product is urgently needed to inhibit bacteria. The invention is a technical proposal for solving the defects of the prior art, and is a potential drug capable of replacing the prior antibiotics to inhibit streptococcus mitis.
Experiments show that the epilithocholic acid has good activity of inhibiting streptococcus mitis.
Drawings
Fig. 1: and (3) a graph of the relationship between the concentration of the epilithocholic acid and the growth inhibition rate of streptococcus mitis.
Fig. 2: a graph of chloramphenicol concentration versus growth inhibition rate of streptococcus mitis.
Detailed Description
The invention is illustrated below with reference to examples, in which an in vitro antibacterial activity test was performed on lithocholic acid using a trace broth double dilution method, and the antibacterial activity against streptococcus mitis was examined, and experimental system evaluation was performed on chloramphenicol as a control.
Test article and control
1.1 test article
Name: and (3) table lithocholic acid, which is commercially available.
Before the test sample is used, ethanol is used for preparing the test sample into 5mg/mL of maximum concentration, and the test sample is diluted in double in sequence.
1.2 control
Name: chloramphenicol, commercially available.
(II) test Strain and method for culturing the same
2.1 Strain: streptococcus mitis ATCC49456
2.2 sources of strain: purchased from Beijing Bai Ou Bo Wei Biotechnology Co.
2.3 culture conditions: todd-HewittBroth, incubation at 37℃for 24h-48h.
2.4 starting seed and culturing the strain
The outside of the penicillin bottle is wiped by 75% alcohol cotton, and a plastic cover and an aluminum cover are removed by using a nipper pliers in a safety cabinet. Slowly opening the rubber plug, sterilizing the bottle mouth part with 75% alcohol cotton, injecting 0.5ml liquid culture medium re-dissolving freeze-dried powder with a sterile straw, inoculating the suspension on the culture medium, culturing at 37 ℃ for 24 hours, and then picking single bacterial colony to culture and increase bacteria in the liquid culture medium under the same culture condition.
2.5 preparation of working solution of bacterial liquid
When the OD600 value reaches about 0.5 (about 10 9 CFU/ml), subjecting to gradient dilution (0, 10, 100, 1000, 10000, 100000, 10000 times) with THB broth, inoculating 100 μl of bacterial suspension onto solid culture medium, culturing for 24 hr, counting viable bacteria, calculating bacterial suspension concentration, and diluting the bacterial suspension to obtain bacterial suspension final concentration of about 2×10 6 CFU/ml. The strain operation is carried out under the aseptic condition, and after the experiment is finished, all consumable materials are sterilized and then discarded.
(III) determination of the minimum inhibitory concentration required to inhibit 50% of the test bacteria (MIC 50)
3.1 test method: MIC50 determination was performed by a micro broth dilution method.
The experiments were divided into positive control (i.e. bacterial suspension without drug), negative control (medium with vehicle ethanol) and experimental (bacterial suspension with different concentrations of lithocholic acid). Each of the above groups was provided with 3 parallel groups. The experiment solution of the epilithocholic acid with the concentration of 100 mug/ml is diluted by times in a liquid culture medium to obtain the final concentration of 100 mug/ml, 50 mug/ml, 25 mug/ml, 12.5 mug/ml, 6.25 mug/ml, 3.125 mug/ml and 0 mug/ml. The concentration is 2X 10 6 CFU·mL -1 The bacterial suspension and each group of liquid medicine are respectively inoculated into a sterile 96-well plate according to the proportion of 1:1 and 100 mu L, so that the final concentration of the bacterial suspension is 1 multiplied by 10 6 CFU/ml (containing 10) 5 CFU/well), and cultured under appropriate culture conditions for 20 hours. Meanwhile, chloramphenicol as a control was set so that its final concentration was 32. Mu.g/ml, 16. Mu.g/ml, 8. Mu.g/ml, 4. Mu.g/ml, 2. Mu.g/ml, 1. Mu.g/ml, and 0. Mu.g/ml, respectively. After the culture is finished, visual observation is carried out under a black background, and the lowest drug concentration without bacterial growth in the plate is the Minimum Inhibitory Concentration (MIC) of the lithocholic acid. MIC determination experiments for all species were repeated 3 times. The method for calculating the OD600 value, the test samples with different concentrations and the control bacteriostasis rate of the suspended bacteria comprises the following steps: antibacterial ratio (%) =1- (test OD value-negative control OD value)/(positive control OD value-negative control OD value) ×100%. The MIC50 is calculated by curve fitting a function.
3.2 judgment of results
The results of this test are shown in Table 1, and the inhibition rates are shown in FIG. 1. The test is only meaningful when the bacteria grow significantly in the positive control wells (i.e. without drug). The results showed that bacteria grew normally in the positive control wells (i.e., without drug) and that the vehicle control medium wells grew aseptically. The MIC value of the control chloramphenicol for Streptococcus mitis was 4. Mu.g/ml, the results are shown in Table 2, and the inhibition ratio is shown in FIG. 2, which meets the "antimicrobial susceptibility test execution Standard" of the American clinical laboratory standardization Committee (National committee for clinical library standardization, NCCLS) 2001: the chloramphenicol in the eleventh edition of information journal M100-S11 is less than or equal to 4 mug/ml for streptococcus mitis, which shows that the experimental method is reliable.
Statistical results show that: the MIC50 of epilithocholic acid for the tested Streptococcus mitis was 6.526 μg/ml. In conclusion, the epilithocholic acid has good activity of inhibiting streptococcus mitis.
TABLE 1 absorbance measurements of the effect of different concentrations of epilithocholic acid on growth of Streptococcus mitis
Table 2: absorbance measurement of the effect of different chloramphenicol concentrations on growth of Streptococcus mitis
Claims (1)
1. Use of epilithocholic acid in the preparation of a medicament against streptococcus mitis ATCC 49456.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210961982.5A CN115350198B (en) | 2022-08-11 | 2022-08-11 | Application of epilithocholic acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210961982.5A CN115350198B (en) | 2022-08-11 | 2022-08-11 | Application of epilithocholic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115350198A CN115350198A (en) | 2022-11-18 |
| CN115350198B true CN115350198B (en) | 2024-01-30 |
Family
ID=84001023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210961982.5A Active CN115350198B (en) | 2022-08-11 | 2022-08-11 | Application of epilithocholic acid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115350198B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112245423A (en) * | 2020-10-21 | 2021-01-22 | 兰州大学 | New application of acylated homoserine lactone compound in treatment of oral diseases |
| CN113559013A (en) * | 2021-09-01 | 2021-10-29 | 南充市中心医院 | Application of lithocholic acid compound in preparation of antibacterial product |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077123B2 (en) * | 2016-02-29 | 2021-08-03 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Use of bile acids and bile salts as anti bacterial agents for inhibition of bacterial conjugation and horizontal gene transfer |
-
2022
- 2022-08-11 CN CN202210961982.5A patent/CN115350198B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112245423A (en) * | 2020-10-21 | 2021-01-22 | 兰州大学 | New application of acylated homoserine lactone compound in treatment of oral diseases |
| CN113559013A (en) * | 2021-09-01 | 2021-10-29 | 南充市中心医院 | Application of lithocholic acid compound in preparation of antibacterial product |
Non-Patent Citations (2)
| Title |
|---|
| Human gut bacteria produce ΤΗ17-modulating bile acid metabolites;Donggi Paik等;《Nature》;第603卷;第907-938页 * |
| The Role of Bile Acid in Improving Glucose Tolerance of Non-Obese Diabetic Rats After Proximal Small Bowel Bypass;Zhihua Zheng等;《Frontiers in Physiology》;第13卷;第1-10页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115350198A (en) | 2022-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nwadioha et al. | A review of bacterial isolates in blood cultures of children with suspected septicemia in a Nigerian tertiary Hospital | |
| Aldons | A comparison of clarithromycin with ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis | |
| Davcheva-Chakar et al. | Adenoid vegetations–reservoir of bacteria for chronic otitis media with effusion and chronic rhinosinusitis | |
| CN113491692A (en) | Application of C-JUN N-terminal kinase inhibitor SU3327 | |
| Dhungana et al. | Detection of Klebsiella pneumoniae carbapenemase (KPC) and metallo betalactamae (MBL) producing Gram negative bacteria isolated from different clinical samples in a Transplant Center, Kathmandu, Nepal | |
| Crombleholme et al. | Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin | |
| Jalil et al. | Inhibitory activity of Mentha spicata oils on biofilms of Proteus mirabilis isolated from burns | |
| Yerat et al. | A clinicomicrobial study of diabetic foot ulcer infections in South India | |
| CN115350198B (en) | Application of epilithocholic acid | |
| CN115381841B (en) | Application of lithocholic acid | |
| US20070264247A1 (en) | Use of Human Lysozyme in Preparation of Medicine for Treating Acne | |
| CN115252627B (en) | Application of lithocholic acid | |
| Ngu Ngwa et al. | Bacterial pathogens involved in bovine mastitis and their antibiotic resistance patterns in the Adamawa region of Cameroon | |
| Ardicli et al. | Pathogens isolated from bovine clinical mastitis and their antimicrobial resistance. | |
| Van Bijsterveld et al. | Fusidic acid in infections of the external eye | |
| Nedbalcová et al. | The determination of minimum inhibitory concentrations of selected antimicrobials for porcine Haemophilus parasuis isolates from the Czech Republic | |
| CN115531394B (en) | Application of deoxycholic acid in preparation of product for resisting streptococcus mitis | |
| CN115364107B (en) | Application of lithocholic acid | |
| CN106860447B (en) | Application of riluzole in inhibiting staphylococcus aureus | |
| CN112353820B (en) | Application of novel ST-type CRPA strain | |
| de Vries-Hospers et al. | Influence of quinolones on throat-and faecal flora of healthy volunteers | |
| CN115569141B (en) | Application of deoxycholic acid in preparation of oral streptococcus resistant product | |
| Kotgire et al. | Aerobic bacteriological profile and its antimicrobial sensitivity pattern from blood culture specimens in a tertiary care hospital | |
| CN115531395B (en) | Application of deoxycholic acid in preparation of product for resisting streptococcus infantis | |
| Bukhari et al. | Multi-drug resistant Ewingella americana |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |